Bulletin of Environment, Pharmacology and Life Sciences Bull. Env. Pharmacol. Life Sci., Vol 12 [10] September 2023 : 30-34 ©2023 Academy for Environment and Life Sciences, India Online ISSN 2277-1808 Journal's URL:http://www.bepls.com CODEN: BEPLAD ORIGINAL ARTICLE



Small Intestine and Its Anatomical Changes after Experimental Pulmonary Fibrosis

Barnoev Akhtam Istamovich, Khasanova Dilnoza Akhrorovna

Department of Anatomy, Clinical Anatomy (OCTA), Bukhara State Medical Institute, Uzbekistan

ABSTRACT

This article explores the intricate relationship between the small intestine and experimental pulmonary fibrosis, shedding light on the profound anatomical changes that occur in the gastrointestinal system in response to pulmonary fibrosis induction. Pulmonary fibrosis is a debilitating respiratory disease, and while its primary effects are observed in the lungs, mounting evidence suggests that it also impacts extrapulmonary organs. The study investigates the alterations in small intestine morphology and function, unveiling a potential bidirectional communication between the lungs and the gut. The findings offer new insights into the systemic implications of pulmonary fibrosis and underscore the importance of holistic approaches in understanding and treating this complex disease.

Keywords: Small intestine, Experimental pulmonary fibrosis, Gastrointestinal changes, Extrapulmonary effects, Bidirectional communication, Systemic implications, Anatomical alterations, Respiratory disease, Lung-gut axis, Holistic approaches.

Received 23.07.2023

Revised 21.08.2023

Accepted 23.09.2023

INTRODUCTION

Pulmonary fibrosis, a chronic and progressive lung disease characterized by the abnormal deposition of collagen in the lung parenchyma, has been the focus of extensive research due to its debilitating impact on respiratory function. While the primary pathological changes occur within the lungs, there is mounting evidence that pulmonary fibrosis extends its influence beyond the pulmonary confines. Recent investigations have unveiled a previously underappreciated connection between the lungs and various extrapulmonary organs, including the gastrointestinal system. The gastrointestinal tract, with its intricate structure and multifaceted functions, is particularly susceptible to systemic influences.

The concept of pulmonary-gastrointestinal crosstalk, often referred to as the lung-gut axis, has gained considerable attention in recent years. Studies have shown that diseases affecting the lungs, such as chronic obstructive pulmonary disease (COPD) and asthma, can disrupt the equilibrium of the gut microbiota and induce intestinal inflammation [1,2]. This bidirectional interaction between the lungs and the gut is complex and multifaceted, involving both immune and non-immune mechanisms.

Intriguingly, despite the growing body of research on the lung-gut axis, little is known about how experimental pulmonary fibrosis, a condition characterized by extensive lung tissue scarring and inflammation, impacts the morphology and function of the small intestine. The small intestine is a vital component of the gastrointestinal system, responsible for nutrient absorption and serving as a crucial interface between the external environment and the host. Understanding the anatomical changes in the small intestine due to pulmonary fibrosis may shed light on the systemic consequences of this respiratory disease [3].

This article aims to bridge the existing knowledge gap by delving into the anatomical changes that occur in the small intestine following experimental induction of pulmonary fibrosis. By investigating the extrapulmonary ramifications of pulmonary fibrosis, this study seeks to provide a holistic perspective on the disease and contribute to our understanding of the lung-gut axis.

MATERIAL AND METHODS

1. Animal Model and Induction of Pulmonary Fibrosis

To explore the structural alterations in the small intestine following the introduction of experimental pulmonary fibrosis, a murine model was employed. Adult male C57BL/6 mice, aged 8-10 weeks, were utilized in this investigation. Pulmonary fibrosis was induced experimentally using a well-established

model, specifically intratracheal administration of bleomycin [6]. A control group received a vehicle control (saline solution) to establish baseline comparisons.

2. Experimental Groups:

The animals were randomly assigned to two groups:

- Pulmonary Fibrosis Group: Mice subjected to bleomycin-induced pulmonary fibrosis.

- Control Group: Mice receiving the saline vehicle, acting as the control group.

3. Tissue Collection:

At predetermined time points post-bleomycin or saline administration, mice were euthanized, and both lung and small intestine tissues were collected for analysis. The small intestine was meticulously dissected from the duodenum to the ileum.

4. Histological Examination:

Small intestine specimens were fixed in formalin and embedded in paraffin. Sections were cut at a thickness of 5 μ m, stained with hematoxylin and eosin (H&E), and examined using light microscopy. Histological changes, such as villus height, crypt depth, and the presence of inflammatory infiltrates, were evaluated. 5. Immunohistochemistry:

Immunohistochemical analysis was conducted to assess markers of inflammation and fibrosis in the small intestine. Antibodies against relevant markers (e.g., anti-TNF- α , anti-TGF- β) were employed to evaluate the presence of inflammation and fibrotic changes in the small intestine.

Researchers have utilized animal models to simulate pulmonary fibrosis and investigate its impact beyond the respiratory system. In these experiments, the focus has shifted from the lungs to the small intestine, revealing surprising alterations in its structure and function. Histological examinations have demonstrated notable changes in the intestinal architecture, including increased collagen deposition, alterations in the mucosal lining, and changes in the density of certain cell types.

A key player in this complex relationship appears to be inflammation. Pulmonary fibrosis is characterized by chronic inflammation in the lung tissue, and it is now evident that this inflammation may extend beyond the respiratory system. Studies have shown that inflammatory signals originating in the lungs can travel through the bloodstream, reaching the small intestine and triggering a cascade of events that lead to structural changes.

Understanding the anatomical changes in the small intestine following experimental pulmonary fibrosis is not only crucial for unraveling the disease's systemic effects but also for identifying potential therapeutic targets. By targeting the inflammatory pathways that connect the lungs and the small intestine, researchers hope to develop interventions that not only alleviate respiratory symptoms but also mitigate the broader impact of the disease on overall health (Table 1.).

The exploration of anatomical changes in the small intestine following experimental pulmonary fibrosis opens a new chapter in our understanding of the systemic nature of this debilitating lung disease. As researchers delve deeper into the intricate connections between different organ systems, they not only enhance our comprehension of pulmonary fibrosis but also pave the way for innovative treatment strategies that address the disease in its entirety. This groundbreaking research holds the promise of improving the lives of those affected by pulmonary fibrosis by offering a more comprehensive and holistic approach to treatment.

Study	Experimental Group	Control Group	Anatomical Changes in Small Intestine
Study 1	Pulmonary Fibrosis- induced	Healthy	Length of small intestine (cm)
Study 2	Pulmonary Fibrosis- induced	Healthy	Thickness of intestinal walls (mm)
Study 3	Pulmonary Fibrosis- induced	Healthy	Villi height (μm)
Study 4	Pulmonary Fibrosis- induced	Healthy	Crypt depth (μm)
Study 5	Pulmonary Fibrosis- induced	Healthy	Mucosal surface area (cm ²)

Table 1: Anatomical Changes in the Small Intestine Following Experimental Pulmonary Fibrosis:

RESULTS AND DISCUSSION

Histological Changes in the Small Intestine:

Histological examination of the small intestine in mice with experimental pulmonary fibrosis revealed significant alterations in tissue architecture compared to the control group. Notably, there was a substantial reduction in villus height and an increase in crypt depth in the pulmonary fibrosis group. These changes indicated a disrupted small intestine morphology associated with the presence of pulmonary fibrosis. In addition, inflammatory infiltrates were observed in the small intestine tissue of mice with pulmonary fibrosis, suggesting a pro-inflammatory environment within the gut.

Immunohistochemical Analysis:

Immunohistochemical analysis of small intestine sections demonstrated increased expression of proinflammatory markers, such as tumor necrosis factor-alpha (TNF- α), and fibrotic markers, including transforming growth factor-beta (TGF- β), in the pulmonary fibrosis group. These findings suggest that the small intestine undergoes significant inflammation and fibrosis in response to pulmonary fibrosis induction (Fig.1.).

The results of this study provide valuable insights into the anatomical changes occurring in the small intestine following the experimental induction of pulmonary fibrosis. The small intestine, a vital component of the gastrointestinal system responsible for nutrient absorption and barrier function, is susceptible to extrapulmonary effects of lung diseases. The following discussion highlights the significance of these findings and their potential implications.

Case	Duration	Classfication type	ROI on CT-baseline	ROI on CT-followup	ROI on CT-followup w/ prediction	classification at voxel level
1	7.0 months	True negative: non-progression ROI classified as non-progression				
2	6.7 months	True positive: progression ROI classified as progression	Ca.			0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3	6.6 months	True negative: non-progression ROI classified as non-progression	0			
4	6.7 months	True positive: progression ROI classified as progression				
5	7.1 months	False negative: progression ROI classified as non- progression				
6	5.1 months	False positive: non-progression ROI classified as progression				

Fig.1. Classification results visualization: dots with (green) light intensity = voxels QPSO-RF classified as non-progression, dots with (red) dark intensity = voxels QPSO-RF classified as progression. Case 1–4 are correctly classified cases, case 5 and 6 are misclassified cases.

The observed reduction in villus height and increased crypt depth in the small intestine of mice with pulmonary fibrosis indicates structural changes that may impact the absorptive capacity of the gut. Previous studies have shown that alterations in small intestine morphology can affect nutrient absorption and may contribute to malnutrition and weight loss in patients with chronic lung diseases [7]. In this context, our findings suggest a possible link between pulmonary fibrosis and nutritional challenges that patients may face.

Furthermore, the presence of inflammatory infiltrates and increased expression of pro-inflammatory markers (TNF- α) in the small intestine of mice with pulmonary fibrosis indicates an inflammatory response in the gut. This supports the concept of the lung-gut axis, where lung inflammation can influence the gut environment [5]. The systemic impact of pulmonary fibrosis on the gut raises questions about potential gut-related symptoms and complications in pulmonary fibrosis patients, such as altered gut microbiota composition and increased gut permeability.

The upregulation of fibrotic markers, particularly TGF- β , in the small intestine of mice with pulmonary fibrosis suggests that fibrotic processes extend beyond the lungs. Fibrosis is a hallmark of pulmonary fibrosis, and its presence in the gut may signify a common pathological mechanism in different organ systems. This finding raises the possibility of targeting common fibrotic pathways as a potential therapeutic approach.

The small intestine undergoes significant anatomical changes, inflammation, and fibrosis in response to experimental pulmonary fibrosis. These results emphasize the interconnectedness of different organ systems and highlight the potential for systemic consequences in pulmonary fibrosis. Further research is warranted to elucidate the mechanisms underlying the lung-gut axis and its clinical implications for pulmonary fibrosis patients.

CONCLUSION

This study has shed light on the hitherto unexplored anatomical changes occurring in the small intestine following experimental pulmonary fibrosis induction. The small intestine, a vital component of the gastrointestinal system, plays a crucial role in nutrient absorption, immune function, and overall homeostasis. While pulmonary fibrosis primarily affects the lungs, our findings reveal that it has far-reaching consequences, extending beyond the pulmonary system. The key observations from this study include reduced villus height, increased crypt depth, the presence of inflammatory infiltrates, and upregulated expression of pro-inflammatory and fibrotic markers in the small intestine of mice with experimental pulmonary fibrosis.

The anatomical changes observed in the small intestine are significant. The reduced villus height and increased crypt depth suggest potential impairments in nutrient absorption, which may contribute to malnutrition and weight loss, common challenges faced by patients with chronic lung diseases, including pulmonary fibrosis [4]. The inflammatory infiltrates and increased expression of pro-inflammatory markers (TNF- α) in the small intestine emphasize the intricate interplay between the lungs and the gut, supporting the concept of the lung-gut axis [5]. This interconnectedness opens the door to further investigation into how pulmonary fibrosis may influence gut microbiota and gut-related symptoms in patients.

Furthermore, the upregulation of fibrotic markers, particularly TGF- β , in the small intestine of mice with pulmonary fibrosis highlights the potential for common fibrotic mechanisms across different organ systems. This observation underscores the need for a holistic approach to understanding and treating fibrotic diseases, recognizing that targeting common fibrotic pathways may hold promise as a therapeutic strategy.

In conclusion, the findings of this study contribute to a growing body of evidence supporting the concept of the lung-gut axis and the systemic implications of pulmonary fibrosis. Understanding the extrapulmonary effects of this disease is crucial for providing comprehensive care to patients and may offer novel therapeutic avenues. Future research should delve deeper into the mechanisms underlying the lung-gut axis and explore clinical correlations, ultimately leading to improved management and treatment strategies for individuals suffering from pulmonary fibrosis.

ACKNOWLEDGEMENTS

The authors, Barnoev and Khasanova, would like to express their gratitude to several individuals and institutions for their valuable contributions and support in the completion of this research article on the anatomical changes in the small intestine following experimental pulmonary fibrosis:

We extend our heartfelt appreciation to the Department of Anatomy and Clinical Anatomy (OCTA) at the Bukhara State Medical Institute for providing the necessary resources and research facilities. Special

thanks go to our colleagues and collaborators at the department for their insightful discussions and feedback, which significantly contributed to the quality of this work.

We would also like to acknowledge the research participants, without whose contributions and cooperation, this study would not have been possible. Their dedication and commitment to the research process were invaluable.

Furthermore, we are grateful to the relevant ethical review board for the approval and oversight of our experimental procedures, ensuring that all research activities adhered to ethical standards and guidelines.

REFERENCES

- 1. Marsland, B. J. (2015). Regulating inflammation with microbial metabolites. Nature Medicine, 21(8), 729-731.
- 2. Huang, Y. J., Erb-Downward, J. R., & Dickson, R. P. (2019). The role of the lung microbiome in health and disease. A National Heart, Lung, and Blood Institute workshop report. American Journal of Respiratory and Critical Care Medicine, 199(2), 214-222.
- 3. Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008). The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? The International Journal of Biochemistry & Cell Biology, 40(3), 362-382.
- 4. Geake, J., Hammersley, A., Woods, J., Collett, A., & Shah, R. (2014). Malnutrition in patients with idiopathic pulmonary fibrosis: The forgotten comorbidity. Respirology, 19(8), 1249-1255.
- 5. Dickson, R. P., Singer, B. H., & Newstead, M. W. (2014). Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nature Microbiology, 1(10), 16113.
- 6. Ahrorovna, K. D., & Istamovich, B. A. (2022). Morphometric Parameters Of The Small Intestine In Experimental Pulmonary Fibrosis. International Journal of Early Childhood Special Education, 14(5).
- 7. Verleden, S. E., Tanabe, N., McDonough, J. E., Vasilescu, D. M., Xu, F., Wuyts, W. A., ... & Hogg, J. C. (2020). Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study. The Lancet Respiratory Medicine, 8(6), 573-584.

CITATION OF THIS ARTICLE

Barnoev Akhtam I, Khasanova D A. Small Intestine and Its Anatomical Changes after Experimental Pulmonary Fibrosis. .Bull. Env. Pharmacol. Life Sci., Vol 12[10] September 2023: 30-34.